What is Beraprost?

Beraprost is a medicine that is still in clinical studies for the treatment of pulmonary hypertension in early phase (PH), peripheral vascular disease in early phase (PVD) and reperfusion damage. The drug is a synthetic form of chemicals called prostacycline, produced naturally by the body in endothelial cells. It promotes the vasodilation of blood vessels by releasing cells of the smooth muscles of the walls of the blood vessels. This reduces the pressure on the blood vessels, helping to reduce blood pressure.

There is a reperfusion damage when blood flow is restored to the tissue after the period in which it was limited. Sudden blood flow into the tissue causes inflammation and oxidative stress occurs in the affected tissue. Berapropne can help spread the blood vessels that normally supply oxygen and nutrients to this tissue, and can be able to prevent damage caused by inflammation and lack of oxygen.

Peripheral vascular disease is a narrowing of blood vessels to arms, legs and internal organs such as stomach and kidneys. The initial phase of this disease begins with a crampthe way or heavy weakness in the feet during activity. Oily blocking in blood vessels cause limited blood circulation. Scientists believe that the vasodilation properties of Beraprost can lead to improvement of blood flow and oxygenation of the affected tissues.

The

lung hypertension results in an increase in blood pressure on the lung system through the pulmonary artery, vein and capillary. Increased pressure is referred to as lung vasculature. Beraprost is given to reduce the internal pressure in the blood vessels, leading to a more affordable oxygen for the use of the body. Untreated pulmonary hypertension can lead to dizziness, fainting and breathing problems. Heavy cases can even lead to death.

Patients attending clinical trials were able to walk after a longer distance in six -minute attempts than on placebo. This causes an increased level of oxygenation among the people who received Beraprost in the study. Positive effectslasted until the medicine continued. Those people who were on placebo had a drop in the distance they could walk for the same time.

patients in the study reported some side effects, including headaches, dizziness and flushing of face and chest. Some people reported diarrhea and nausea when taking medication. There were also several reports of jaw pain and foot pain that retreated when the drug was interrupted.

Beraprost's safety profile in a clinical study was presented as excellent. There were no signs of systemic hypotension or kidney damage among those in the study. The function of the liver has not been affected by the drug. Long -term effects of drugs have not been evaluated.